Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity ...

Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...

US President Trump wraps up his Asia tour with major trade and security announcements, while Israel’s Netanyahu issues a ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Lilly and spawning a ...

Por TOM MURPHYEl mercado de tratamientos para la obesidad y la diabetes sigue siendo extremadamente activo, canalizando miles de millones de dólares en ventas para Eli Lilly y alimentando una ...

LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive ...

Novo Nordisk's surprise bid for Metsera has set the stage for a high-stakes showdown in the obesity drug market, with Pfizer ...

Roblox posted a wider third-quarter loss but boosted its revenue forecast for the year as a pair of videogaming crazes generated robust top-line growth. Fox logged higher revenue in its fiscal first ...

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish ...

Novo Nordisk said on Thursday that it had adhered to all restrictions under the Pfizer merger agreement in its unsolicited ...

Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about ...